Ovid Therapeutics Inc
OVID0.489USD
-0.011-2.18%
交易中 （美东）报价延迟15分钟
34.78M总市值
亏损市盈率 TTM
关于 Ovid Therapeutics Inc 公司
Ovid Therapeutics Inc. 是一家生物制药公司。该公司致力于改善某些癫痫和脑部疾病患者的生活，这些疾病伴有癫痫症状。该公司致力于推进一系列新型靶向小分子候选药物，这些药物可调节引起癫痫和其他神经症状的神经元兴奋过度的内在和外在因素。该公司开发了 OV888 (GV101)，一种强效且高度选择性的 ROCK2 抑制剂，可用于治疗与脑海绵状血管瘤和其他脑部疾病相关的病变；OV329，一种 GABA-氨基转移酶抑制剂，可用于治疗难治性癫痫；OV350，一种 KCC2 转运蛋白的直接激活剂，可用于治疗癫痫和其他精神疾病。该公司还对 Soticlestat 的开发和商业化感兴趣，Soticlestat 是一种用于治疗 Dravet 和 Lennox-Gastaut 综合征的胆固醇 24-羟化酶抑制剂。
公司简介
公司代码OVID
公司名称Ovid Therapeutics Inc
上市日期May 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
员工数量23
证券类型Ordinary Share
年结日May 05
公司地址441 Ninth Avenue, 14Th Floor
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10001
电话12127764381
网址https://ovidrx.com/
公司代码OVID
上市日期May 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Operating Officer
President, Chief Operating Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月23日 周三
更新时间: 7月23日 周三
持股股东
股东类型
持股股东
持股股东
占比
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
持股股东
持股股东
占比
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
股东类型
持股股东
占比
Investment Advisor
16.66%
Hedge Fund
13.33%
Investment Advisor/Hedge Fund
10.93%
Corporation
10.59%
Individual Investor
5.72%
Research Firm
1.65%
Bank and Trust
0.20%
Venture Capital
0.13%
Pension Fund
0.03%
Other
40.74%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
175
46.86M
65.90%
-15.45M
2025Q1
183
51.39M
72.29%
-10.07M
2024Q4
181
52.28M
73.63%
-8.46M
2024Q3
175
51.32M
72.31%
-10.19M
2024Q2
172
51.56M
72.67%
-6.81M
2024Q1
174
55.84M
78.97%
-6.53M
2023Q4
174
57.32M
81.09%
-4.46M
2023Q3
183
57.79M
81.95%
-5.02M
2023Q2
192
56.05M
79.62%
-3.53M
2023Q1
194
53.91M
76.62%
-6.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Takeda Pharmaceutical Co Ltd
7.53M
10.59%
--
--
Mar 31, 2025
Levin (Jeremy M)
3.65M
5.14%
-20.00
-0.00%
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
5.04%
-59.44K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.11M
4.37%
-39.30K
-1.25%
Mar 31, 2025
Madison Avenue Partners LP
2.47M
3.47%
-386.73K
-13.56%
Mar 31, 2025
Sio Capital Management, LLC
2.23M
3.14%
+1.23M
+123.20%
Mar 31, 2025
Acadian Asset Management LLC
2.09M
2.94%
+237.44K
+12.83%
Mar 31, 2025
Kennedy Capital Management LLC
1.73M
2.44%
+187.48K
+12.13%
Mar 31, 2025
Driehaus Capital Management, LLC
1.40M
1.97%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.37M
1.93%
-22.41K
-1.61%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis Responsible US Equity ETF
0%
查看更多
iShares Russell 2000 Growth ETF
占比0%
iShares Micro-Cap ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Avantis Responsible US Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
